Five Prime Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Five Prime Therapeutics, Inc. - overview
Established
2001
Location
South San Francisco, CA, US
Primary Industry
Biotechnology
About
Based in California, US, and founded in 2001, Five Prime Therapeutics, Inc. develops immuno-oncology therapies intended for cancer patients. The company was founded by Lewis Williams and has offices located in San Francisco, US, Cambridge, US, Framingham, US, New York, US, and Seattle, US. In 2013, Five Prime Therapeutics, Inc.
was publicly traded on the NASDAQ Global Market under the symbol FPRX. , and in 2021, the company was acquired by Amgen Inc. Five Prime Therapeutics, Inc. develops therapeutics, under clinical trials, such as bemarituzumab - designed to block tumor growth causing cancer, FPT155 - stimulates anti-tumor immunity for solid tumors, FPA157 – helps enhance antibody-dependent cell-mediated cytotoxicity (ADCC) to eliminate cells causing cancer, and BMS-986258 (or TIM-3) – limits the duration and magnitude of cancer cells.
Current Investors
Advanced Technology Ventures, Domain Associates, Kleiner Perkins
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Company Stage
Acquired
Total Amount Raised
Subscriber access only
Five Prime Therapeutics, Inc. - financials
| Fiscal Year Ended | Dec 31, 2008 | Dec 31, 2009 | Dec 31, 2010 | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 15,600,000 | 21,900,000 | 23,700,000 | 64,900,000 | 10,000,000 | 13,791,000 | 19,231,000 | 379,801,000 | 30,691,000 | 39,508,000 | - | - | - |
| % Revenue Growth (YoY) | - | 40.4% | 8.2% | 173.8% | (84.6%) | 37.9% | 39.4% | 1874.9% | (91.9%) | 28.7% | - | - | - |
| EBITDA (USD) | - | - | (12,200,000) | 22,300,000 | (25,500,000) | (27,295,000) | (34,531,000) | 290,676,000 | (93,283,000) | (147,268,000) | - | - | - |
| Operating Income (USD) | - | - | (14,000,000) | 19,800,000 | (27,700,000) | (29,421,000) | (37,574,000) | 286,973,000 | (99,212,000) | (151,402,000) | - | - | - |
| Operating Margin | - | - | (59.1%) | 30.5% | (277.0%) | (213.3%) | (195.4%) | 75.6% | (323.3%) | (383.2%) | - | - | - |
| % EBITDA Margin | - | - | (51.5%) | 34.4% | (255.0%) | (197.9%) | (179.6%) | 76.5% | (303.9%) | (372.8%) | - | - | - |
| NET Income (USD) | (10,600,000) | (9,800,000) | (13,500,000) | 19,700,000 | (27,600,000) | (28,872,000) | (37,424,000) | 249,647,000 | (65,697,000) | (150,222,000) | - | - | - |
| % Net Margin | (67.9%) | (44.7%) | (57.0%) | 30.4% | (276.0%) | (209.4%) | (194.6%) | 65.7% | (214.1%) | (380.2%) | - | - | - |
Five Prime Therapeutics, Inc. - employee data
Five Prime Therapeutics, Inc. - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Chairman Of The Board Of Directors | BM | ||||||
| Member of the Board of Directors, Compensation Committee member | BM | ||||||
| Chairman of the Board | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.